Monsanto Co. rejected Bayer AG’s $62 billion takeover offer, saying the biotech seed giant’s business merited a higher price, though Monsanto said it remains open to further talks on a deal.
The move, which was widely expected, puts pressure on the German pharmaceutical and chemical conglomerate to sweeten its offer over protests from some of its investors who fear buying Monsanto would deeply indebt Bayer and move the company far deeper into agriculture.
“We believe in the substantial benefits an integrated strategy could provide to growers and broader society, and we have long respected Bayer’s business,” said Monsanto Chief Executive and Chairman Hugh Grant. But he also said the offer “significantly undervalues” Monsanto and doesn’t address certain risks related to a deal, including potential financing and regulatory hurdles.
Bayer detailed Monday its plan to buy Monsanto and add the U.S. company’s world-leading franchise in high-yielding crop seeds and genetic engineering to Bayer’s broad portfolio of insecticides and herbicides. A union would create the world’s largest seed and crop chemical supplier and make agriculture about half of Bayer’s overall sales.
Monsanto said Tuesday its board of directors unanimously viewed Bayer’s proposal as “incomplete and financially inadequate,” but it remains open to “continued and constructive conversations.” The company said no deal was guaranteed.
Full Content: The Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK Probes Lindab’s Acquisition of HAS-Vent Amid Fears of Market Monopoly
Apr 28, 2024 by
CPI
Shein Faces EU Regulations Over User Data
Apr 28, 2024 by
CPI
Google Fights Back Against US Antitrust Lawsuit
Apr 28, 2024 by
CPI
US Homeland Security Establishes Blue-Ribbon Board with Tech CEOs to Advise on AI
Apr 28, 2024 by
CPI
FTC Accuses Amazon Executives of Using Disappearing Messaging Apps to Conceal Evidence
Apr 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI